Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a
population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the
investigators will conduct an open-label, prospective, un-blinded study. The investigators
expect that at least 70% of subjects will tolerate the supplement and complete the trial. The
investigators expect no Serious Adverse Event to occur during this trial which is
attributable to study compound. During this study, the investigators will also collect other
qualitative data to be utilized for future double-blinded studies which will be aimed at
determining whether grade IV astrocytoma patients who receive PolyMVA achieve a better
quality of life during their chemo-therapeutic regimens versus grade IV astrocytoma patients
who do not receive PolyMVA.